Announced new durability data in metastatic colorectal cancer, demonstrating meaningful and sustained clinical benefit in patients with RAS-mutant, microsatellite-stable disease. Oncolytics Biotech Inc shares N.ONCY are trading up $0.08 at $0.95.
Full Press Release: https://www.baystreet.ca/quotedata/quote.aspx?ticker=ONCY&qmodStoryID=7963902581673625